Drugs / LP-005
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06294301 | Nov 2023 → Aug 2024 | paroxysmal nocturnal hemoglobinuria | Longbio Pharma | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07603713 | May → Nov 2026 expected | periodontitis | Longbio Pharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07363265 | Feb 2026 → Aug 2028 expected | — | Longbio Pharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07266155 | Dec 2025 → Dec 2027 expected | paroxysmal nocturnal hemoglobinuria | Longbio Pharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07212426 | Nov 2024 → May 2026 overdue | paroxysmal nocturnal hemoglobinuria | Longbio Pharma | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07363265 ↗ |
| Modality | Protein / enzyme biologic | “LP-005 is a bifunctional antibody fusion protein” NCT07603713 ↗ |
| Route | Intravenous | “administered intravenously.” NCT06294301 ↗ |
| Target | C5 | “anti-human C5 monoclonal antibody” NCT07603713 ↗ |